Crucial Role of NLRP3 Inflammasome in the Development of Peritoneal Dialysis-related Peritoneal Fibrosis

Erika Hishida1,2, Homare Ito1, Takanori Komada1,2, Tadayoshi Karasawa1, Hiroaki Kimura2,4, Sachiko Watanabe1, Ryo Kamata3,5, Emi Aizawa1, Tadashi Kasahara1, Yoshiyuki Morishita3, Tetsu Akimoto2, Daisuke Nagata2 & Masafumi Takahashi1

Long-term peritoneal dialysis (PD) therapy leads to peritoneal inflammation and fibrosis. However, the mechanism underlying PD-related peritoneal inflammation and fibrosis remains unclear. NLRP3 inflammasome regulates the caspase-1-dependent release of interleukin-1β and mediates inflammation in various diseases. Here, we investigated the role of NLRP3 inflammasome in a murine model of PD-related peritoneal fibrosis induced by methylglyoxal (MGO). Inflammasome-related proteins were upregulated in the peritoneum of MGO-treated mice. MGO induced parietal and visceral peritoneal fibrosis in wild-type mice, which was significantly reduced in mice deficient in NLRP3, ASC, and interleukin-1β (IL-1β). ASC deficiency reduced the expression of inflammatory cytokines and fibrotic factors, and the infiltration of macrophages. However, myeloid cell-specific ASC deficiency failed to inhibit MGO-induced peritoneal fibrosis. MGO caused hemorrhagic ascites, fibrin deposition, and plasminogen activator inhibitor-1 upregulation, but all of these manifestations were inhibited by ASC deficiency. Furthermore, in vitro experiments showed that MGO induced cell death via the generation of reactive oxygen species in vascular endothelial cells, which was inhibited by ASC deficiency. Our results showed that endothelial NLRP3 inflammasome contributes to PD-related peritoneal inflammation and fibrosis, and provide new insights into the mechanisms underlying the pathogenesis of this disorder.

Peritoneal dialysis (PD) is a renal replacement therapy used by approximately 200,000 patients with end-stage kidney disease worldwide, accounting for 11% of the PD population. Long-term PD leads to fibrotic changes of the peritoneum with functional decline1,2. In addition, peritoneal fibrosis can, albeit rarely, progress to fibrous encapsulation of the small bowels as a “cocoon”, known as encapsulating peritoneal sclerosis (EPS), which is associated with high morbidity and mortality. The pathological feature of EPS is fibrin deposition due to plasma exudation from peritoneal microvessels3,4. Recent studies have demonstrated that inflammation induced by bio-incompatible PD fluids (PDFs) and/or infections is involved in the pathogenesis of PD-related peritoneal fibrosis4,5. In particular, heat sterilization of conventional PDFs leads to the generation of glucose degradation products (GDPs), such as acetaldehyde, formaldehyde, glyoxal, and methylglyoxal (MGO)6. Of these, MGO is an extremely toxic GDP that causes oxidative stress and peritoneal injury. MGO has also been shown to enhance the production of vascular endothelial growth factor (VEGF), which may lead to vascular permeability and procoagulant activity. Furthermore, MGO administration induces peritoneal fibrosis in experimental rodents, which is frequently used as an animal model of PD-related peritoneal fibrosis7,8. However, the mechanisms underlying inflammation in the development of PD-related peritoneal fibrosis have not been fully understood.

Accumulating body of evidence suggests that inflammation in the absence of pathogens (sterile inflammation) is mediated via the inflammasome; an intracellular multi-protein complex that regulates release of
proinflammatory cytokine interleukin (IL-1β)3–11. Although several pattern recognition receptors (PRRs) can form the inflammasome complex, the nucleotide-binding oligomerization domain-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome is well characterized and has been implicated in sterile inflammatory diseases. The NLRP3 inflammasome contains NLRP3 associated with an apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which recruits caspase-1 and induces its activation. Since caspase-1 is an IL-1β-converting enzyme12, NLRP3 inflammasome-driven caspase-1 activation induces the processing of pro-IL-1β into its mature form, and the release of this potent inflammatory cytokine IL-1β causes tissue inflammation and damage. Furthermore, activation of NLRP3 inflammasome also triggers inflammatory cell death termed as pyroptosis13–11. Our group recently demonstrated that NLRP3 inflammasome is involved in sterile inflammatory responses in cardiovascular and renal diseases13–17. Supporting our findings, recent investigations have also shown that NLRP3 inflammasome is a key mediator of many sterile inflammation-related diseases including gout, atherosclerosis, type 2 diabetes, and metabolic syndrome18. We and other investigators have also shown that NLRP3 inflammasome is involved in the expression of fibrotic factors and the development of tissue fibrosis13,17,19. Additionally, NLRP3 itself has been suggested to contribute to the signaling of transforming growth factor-β (TGF-β) in tubular epithelial cells and to promote renal fibrosis independent of the inflammasome20. Further, Hautem et al.21 recently reported that NLRP3 inflammasome plays a role in transport defects and morphological alterations in PD-related bacterial peritonitis. However, the role of NLRP3 inflammasome in PD-related peritoneal fibrosis remains to be elucidated.

In the present study, we used mice deficient in NLRP3, ASC, and IL-1β, and generated MGO-induced peritoneal fibrosis, which is an excellent murine model for human PD-related peritoneal fibrosis. We clearly showed that deficiency of NLRP3, ASC, or IL-1β reduced inflammatory and fibrotic responses in a MGO-induced peritoneal fibrosis model. MGO also caused peritoneal bleeding and fibrin deposition, and subsequently promoted peritoneal fibrosis, all of these manifestations were inhibited by ASC deficiency. In vitro experiments showed that MGO generated reactive oxygen species (ROS) and induced cell death in endothelial cells, which was inhibited by ASC deficiency. The present findings showed that endothelial NLRP3 inflammasome contributes to peritoneal inflammatory and fibrotic responses in the pathophysiology of PD-related peritoneal fibrosis, and provide new insights into the mechanisms underlying the pathogenesis of this disorder.

**Results**

**Inflammasome-related proteins were up-regulated in MGO-induced peritoneal fibrosis.** To produce a murine model of MGO-induced peritoneal fibrosis, we injected MGO (40 mM) intraperitoneally into wild-type (WT) mice, and Masson’s Trichrome (MT) staining showed that MGO significantly induced fibrous thickening of the parietal peritoneum in a time-dependent manner (Fig. 1a,b). We next assessed the expression of inflammasome-related proteins by using real-time RT-PCR analysis and found that the peritoneal expression of NLRP3, ASC, caspase-1, and IL-1β was elevated in a time-dependent manner, and this increase was statistically significant at 21 days after MGO treatment (Fig. 1c). We also assessed the expression of other inflammasome-forming PRRs, there was no significant differences of the mRNA expression of NLRP1, NLRC4 (NLR family CARD-containing 4), and AIM2 (absent in melanoma 2) between vehicle- and MGO-treated groups (Supplementary Fig. S1). The peritoneal expression of transforming growth factor-β (TGF)-β was also significantly elevated at 14 and 21 days after MGO treatment. To further investigate the peritoneal fibrotic process, we assessed fibrotic changes in the visceral peritoneum and found that MGO induced shrinkage of the mesentery, and its area was apparently decreased after MGO treatment in a time-dependent manner (Fig. 1d,e). Furthermore, some mice exhibited bowel adhesions, a clinical presentation similar to EPS, at 21 days after MGO treatment. Consistently, the expression of inflammasome-related molecules tended to be elevated in the visceral peritoneum after MGO treatment (Fig. 1f).

**Deficiency of NLRP3 or ASC reduced MGO-induced peritoneal fibrosis.** To investigate the role of NLRP3 inflammasome, we used NLRP3−/−, ASC−/−, and IL-1β−/− mice, and found that a deficiency of NLRP3, ASC, or IL-1β partially but significantly reduced MGO-induced fibrosis in the parietal peritoneum (Fig. 2a,b). Because this inhibitory effect was predominantly observed in ASC−/− mice, the following experiments were conducted to assess the phenotypes in WT and ASC−/− mice. Consistent with the findings in the parietal peritoneum, the mesentery area was retained in ASC−/− mice, compared to that in WT mice (Fig. 2c,d).

**ASC deficiency reduced inflammatory and fibrotic responses.** Because inflammatory response is linked to the NLRP3 inflammasome as well as PD-related peritoneal fibrosis22,23, we assessed the expression of inflammatory molecules in the parietal peritoneum, and showed that the mRNA expression of IL-1β, IL-6, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1, and F4/80 (a macrophage marker; Emr1) was markedly increased in the MGO-treated peritoneum of WT mice, but the increased expression of these cytokines and macrophage marker was decreased in ASC−/− mice (Fig. 3a). As expected from the data on fibrosis, similar expression patterns were observed in the expression of collagen type 1 and type 3, fibronectin, TGF-β, matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 (Fig. 3b). Analysis of the visceral peritoneum also showed similar changes in the expression of inflammatory and fibrotic factors (Supplementary Fig. S2).

**ASC deficiency reduced the inflammatory cell infiltration.** Since the components of NLRP3 inflammasome are expressed mainly in inflammatory cells, especially macrophages, we performed an immunohistochemical analysis to analyze infiltrated inflammatory cells. The infiltration of CD45+ (pan-leukocyte marker) and F4/80+ (macrophage marker) cells, but not Ly6G+ (neutrophil marker) or CD3+ (T cell marker) cells, was markedly increased in the parietal peritoneum of MGO-treated WT mice (Fig. 4a). The infiltration of CD45+ cells was significantly lower in ASC−/− mice (Fig. 4b). Consistently, analysis of the visceral peritoneum showed a reduction in the infiltration of CD45+ cells in ASC−/− mice (Fig. 4c). These data suggest that ASC deficiency reduces inflammatory cell infiltration in PD-related peritoneal fibrosis.
and F4/80+ cells was significantly inhibited in ASC−/− mice (Fig. 4b,c). Furthermore, double immunofluorescence staining revealed the colocalization of ASC with F4/80+ cells (Fig. 4d).

**Myeloid cell-specific ASC deficiency had no effect on MGO-induced peritoneal fibrosis.** To determine the contribution of the macrophage NLRP3 inflammasome, we used two different strategies: bone marrow transplantation (BMT) and myeloid cell-specific ASC−/− mice. First, we generated 3 types of BMT mice (BMTWT to WT, BMT ASC−/− to WT, BMTWT to ASC−/−) and produced MGO-induced peritoneal fibrosis in these mice. Unfortunately, MGO treatment caused chylous ascites in these BMT mice (Supplementary Fig. S3A,B). Furthermore, thickness of the parietal peritoneum did not differ between these groups (Supplementary Fig. S3C,D). Second, we generated myeloid cell-specific ASC−/− mice (ASCf/f;LysMcre/+ using the Cre-loxP gene-targeting technique (Fig. 5a, Supplementary Fig. S4). The expression of ASC mRNA and protein was markedly decreased in bone marrow-derived macrophages (BMDMs) isolated from ASCf/f;LysMcre/+ mice, compared
to those from ASC^{−/−};LysM^{Cre/−} mice (Fig. 5b,c). In addition, IL-1β production in response to an NLRP3 activator nigericin was also inhibited in ASC^{−/−};LysM^{Cre/+} mice (Supplementary Fig. S5). Contrary to our expectations, myeloid cell-specific ASC deficiency had no significant effect on MGO-induced peritoneal fibrosis (Fig. 5d,e). Furthermore, the expression levels of IL-1β, collagen type 1, and fibronectin in the peritoneum did not differ between ASC^{−/−};LysM^{Cre/−} and ASC^{−/−};LysM^{Cre/+} mice (Fig. 5f).

ASC deficiency exhibited less peritoneal bleeding and fibrin deposition. Previous investigations have suggested that endothelial cells play a role in the development of PD-related peritoneal fibrosis. Indeed, we observed that MGO treatment caused hemorrhagic ascites in a time-dependent manner (Fig. 6a) and the red blood cell (RBC) counts in the peritoneal lavage were significantly increased at 21 days after MGO treatment (Fig. 6b). This MGO-induced hemorrhagic ascites was considerably prevented in ASC^{−/−} mice (Fig. 6c,d). To determine whether endothelial cells express ASC, we performed an immunohistochemical analysis and found that serial sections stained for CD34 (endothelial marker) revealed that ASC was expressed in endothelial cells (Fig. 6e). Fibrin deposition was also increased in the MGO-treated peritoneum of WT mice, and this deposition was markedly decreased in the peritoneum of ASC^{−/−} mice (Fig. 6f). Furthermore, the expression of plasminogen activator inhibitor -1 (PAI-1), a marker for endothelial dysfunction, was significantly increased in the MGO-treated peritoneum of WT mice, whereas this increase was inhibited in ASC^{−/−} mice (Fig. 6g).
Roles of endothelial ROS generation, cell death, and IL-1β. To explore the mechanism by which ASC deficiency prevents MGO-induced peritoneal fibrosis, we used two types of cultured endothelial cells: human umbilical vein endothelial cells (HUVECs) and murine lung vascular endothelial cells (MLVECs). Because we could not observe MGO-induced IL-1β production in HUVECs and MLVECs primed with or without lipopolysaccharide (data not shown), we then focused on endothelial cell death and found that MGO (1 mM) treatment clearly induced cell death of HUVECs in a time-dependent manner (Fig. 7a,b). IL-1β treatment also induced cell death and additively enhanced MGO-induced cell death. Because MGO has been shown to generate ROS, we assessed ROS levels using the 2',7'-dichlorofluorescein diacetate (DCFDA) method and showed that MGO significantly promoted ROS generation in HUVECs (Fig. 7c). Furthermore, MGO-induced cell death was significantly inhibited by pretreatment with the antioxidant N-acetyl cysteine (NAC) (Fig. 7d). To assess whether ASC deficiency could inhibit MGO-induced cell death, we prepared primary MLVECs (CD45–CD31+ ASC+/–) from WT and ASC–/– mice by using negative immune-magnetic selection (Fig. 7e). MGO treatment induced cell death in WT MLVECs, which was prevented by ASC–/– MLVECs (Fig. 7f,g).

Figure 3. ASC deficiency reduced inflammatory and fibrotic responses. WT and ASC–/– mice were injected with vehicle or MGO for 21 days. (a) mRNA expression of IL-1β, IL-6, TNF-α, MCP-1, and Emr1 in the parietal peritoneum was assessed by using real-time RT-PCR analysis (n = 3–8 for each). (b) mRNA expression of collagen type 1 and 3, fibronectin, TGF-β1, MMP-2, MMP-9, and TIMP-1 in the parietal peritoneum was assessed (n = 3–8 for each). Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4. ASC deficiency reduced the inflammatory cell infiltration. WT and ASC−/− mice were injected with vehicle or MGO for 21 days. (a) Sections of the parietal peritoneum in WT mice were immunohistochemically stained with antibodies against CD45, F4/80, Ly6G, and CD3. (b) Sections of the parietal peritoneum in WT and ASC−/− mice were immunohistochemically stained with antibodies against CD45 and F4/80. (c) Quantitative analysis of CD45- and F4/80-positive cells (n = 3-4 for each). (d) Sections of the parietal peritoneum in WT mice were analyzed by double-immunofluorescence staining with antibodies against F4/80 (green) and ASC (red). DAPI (blue) indicates nuclear staining. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01.
Discussion
The major findings of this study are as follows: 1) Inflammasome-related proteins were upregulated in the peritoneum of MGO-treated mice; 2) MGO induced parietal and visceral peritoneal fibrosis in WT mice, and this fibrosis was significantly reduced in mice deficient in NLRP3, ASC, and IL-1β; 3) ASC deficiency reduced the expression of inflammatory cytokines and fibrotic factors, and the infiltration of macrophages; however, the myeloid cell-specific ASC deficiency failed to inhibit MGO-induced peritoneal fibrosis; 4) MGO caused hemorrhagic ascites, fibrin deposition, and the expression of PAI-1, and all of these manifestations were inhibited by ASC deficiency; and 5) In vitro experiments showed that MGO induced cell death via the generation of ROS in endothelial
cells, which was inhibited by ASC deficiency. The present results indicate that NLRP3 inflammasome plays a crucial role in inflammatory and fibrotic responses in the development of PD-related peritoneal fibrosis, and provide new insights into the mechanism underlying the pathogenesis of PD-related peritoneal fibrosis.

Figure 6. ASC deficiency was associated with less peritoneal bleeding and fibrin deposition. (a–d) WT and ASC−/− mice were injected with vehicle or MGO for the indicated periods. (a) Representative images of peritoneal effluents in WT mice. (b) Quantitative analysis of RBC count in the peritoneal effluents in WT mice (n = 3–8 for each). (c) Representative images of peritoneal effluents in WT and ASC−/− mice (n = 4–6 for each). (d) Quantitative analysis of RBC count in the peritoneal effluents in WT and ASC−/− mice. (e) Sections of the parietal peritoneum in WT mice were analyzed by double-immunofluorescence staining with antibodies against CD34 (green) and ASC (red). DAPI (blue) indicates nuclear staining. Arrowheads and open arrowheads indicate endothelial cells and infiltrated macrophages, respectively. (f) Representative images of phosphotungstic acid-hematoxylin (PTAH) staining for fibrin deposition in the parietal peritoneum. (g) mRNA expression of PAI-1 in the parietal peritoneum was assessed by using real-time RT-PCR analysis (n = 3–8 for each). Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
after MGO treatment, resulting in less peritoneal fibrosis in a murine model of PD-related peritoneal fibrosis and EPS. Several murine models are commonly used to study the pathogenesis of PD-related peritoneal fibrosis including the administration of chlorhexidine gluconate (CG), acidic (pH 3.8) glucose solution, and MGO. Although some histological features of PD-related peritoneal fibrosis are seen in these models, it is accepted that MGO-induced peritoneal fibrosis is more appropriate for studying the pathogenesis of PD-related peritoneal fibrosis because conventional PD fluids contain GDPs including MGO. In addition, the MGO model exhibits histological hallmarks similar to those of PD-related peritoneal fibrosis, such as thickening of the submesothelial compact zone, infiltration of inflammatory cells, capillary angiogenesis, and fibrin deposition. Intriguingly, in addition to these histological features, we found that MGO treatment induces shrinkage of the mesentery and bowel adhesions, which are clinical presentations similar to those in EPS, and these are inhibited by ASC deficiency. To our knowledge, this study provides the first evidence that NLRP3 inflammasome plays a role in sterile peritoneal inflammation and subsequent fibrosis in PD-related peritoneal fibrosis and EPS.

Recent investigations have suggested that inflammatory cells, particularly macrophages, contribute to the process of peritoneal fibrosis. Moreover, because the NLRP3 inflammasome is thought to play a role mainly...
in inflammatory cells, we assessed MGO-induced peritoneal fibrosis in myeloid cell-specific ASC-deficient mice. Unexpectedly, however, myeloid cell-specific ASC deficiency failed to inhibit MGO-induced inflammatory and fibrotic responses, and subsequent peritoneal fibrosis. Supporting this, Huen et al. previously reported that macrophage-specific deletion of TGF-β3 did not prevent renal fibrosis after ischemia-reperfusion or obstructive injury. Nezu et al. also reported that myeloid-specific Keap1 deletion had no effect on tubular damage in ischemia-reperfusion kidneys while tubule-specific Keap1 deletion ameliorated kidney tubular damage. These reports suggest that other cell types likely contribute to the development of fibrosis. We then focused on vascular endothelial cells for the following reasons. First, we observed that ASC deficiency had inhibitory effects on endothelial cell damage, such as hemorrhagic ascites, fibrin deposition, and the expression of PAI-1. Fibrin is considered to be derived from plasma exudation from peritoneal microvessels. In addition, the levels of PAI, an inhibitor of fibrinolysis, have been shown to be increased in patients with PD and correlated with the duration of treatment. Second, recent studies have suggested that NLRP3 inflammasome-driven inflammatory response and cell death can occur in vascular endothelial cells. Furthermore, endothelial damage and angiogenesis are known to be the hallmarks of PD-related peritoneal fibrosis and EPS. Using human and murine primary vascular endothelial cells, we showed that MGO markedly induces cell death through ROS generation, which is prevented by ASC deficiency, suggesting that endothelial NLRP3 inflammasome contributes to the process of PD-related peritoneal fibrosis. Several limitations of this study should be noted. First, although we showed that NLRP3 deficiency significantly attenuates MGO-induced peritoneal fibrosis, we have not examined whether deficiency of other inflammasome-forming PRRs, such as NLRP1, NLRC4, and AIM2, could inhibit peritoneal fibrosis. In this regard, we observed no significant changes of these molecules in mice after MGO treatment; therefore, we assume that NLRP1, NLRC4, and AIM2 inflammasomes are less likely to be involved in MGO-induced peritoneal fibrosis. Second, although MGO-induced peritoneal fibrosis was significantly attenuated in IL-1β-deficient mice, we could not detect substantial IL-1β production in response to MGO in cultured endothelial cells (data now shown). Third, although we clearly showed that MGO induced ASC-dependent cell death in endothelial cells, its mechanism remains to be elucidated. Recent investigations have indicated that the inflammasome activation induces a particular form of cell death called pyroptosis by the cleavage of gasdermin D. On the other hand, ASC has shown to be involved in other types of cell death, such as caspase-8-mediated apoptosis or necrosis distinct from necroptosis. Thus, further studies are needed to elucidate the precise mechanism and role of NLRP3 inflammasome in PD-related peritoneal fibrosis.

In conclusion, the present study demonstrates that NLRP3 inflammasome triggers vascular endothelial cell damage and subsequent peritoneal inflammatory and fibrotic responses, resulting in MGO-induced peritoneal fibrosis. These findings identify NLRP3 inflammasome as a potential novel target for preventing and treating PD-related peritoneal fibrosis and provide new insights into the mechanism underlying this disorder.

Materials and Methods

Animal protocols. All animal experiments were approved by the Use and Care of Experimental Animals Committee of the Jichi Medical University (permit number 17151), and carried out in accordance with Jichi Medical University guidelines. NLRP3−/−, ASC−/−, and IL-1β−/− mice were kindly provided by Drs. Vishava M. Dixit (Genentech, South San Francisco, CA), Shun’ichiro Taniguchi (Shinshu University, Matsumoto, Japan), and Yoichi Ikawara (Tokyo University of Science, Chiba, Japan), respectively. WT mice obtained from Japan SLC, Inc. (Tokyo, Japan) or ASC+/− littermates were used. A similar degree of MGO-induced peritoneal thickness was observed in WT mice and ASC−/− littermates. ASC−/− mice were generated by homologous recombination at Phoenix Bio Co. (Utsunomiya, Japan) and crossed with LysMcre/+ mice (Jackson Laboratories, Bar Harbor, ME). The genetic background of all mice was C57BL/6J and 8- to 10-week-old female mice were used. Mice were housed (4/cage, RAIR HD ventilated Micro-Isolator Animal Housing Systems, Lab Products, Seaford, DE) in an environment maintained at 23 ± 2 °C with ad libitum access to food and water under a 12 h-light and dark cycle with lights on from 8:00 to 20:00. To induce peritoneal fibrosis, mice were injected with peritoneal dialysis fluid (PDF) (100 mL/kg) containing 40 mM MGO solution (Sigma-Aldrich, St. Louis, MO) for a total of 3 weeks, 5 distinct from necroptosis. Thus, further studies are needed to elucidate the precise mechanism and role of NLRP3 inflammasome in PD-related peritoneal fibrosis.

Assessment of mesentery. After the mice were euthanized and peritoneal samples were collected, the intestine was put aside by a cotton swab and cut by forceps at the site of the superior mesenteric artery. The intestine was then washed with phosphate-buffered saline (PBS), and the mesentery was extended as much as possible by cotton swabs. All of the procedures were done carefully so as not to damage the tissue. Images of the mesentery were obtained, and the area of mesentery was quantified by Adobe Photoshop CS software (ver. 8, Adobe Systems Inc., San Diego, CA).

Histology and immunohistochemistry. The peritoneum was fixed with 4% paraformaldehyde and embedded in paraffin. The tissue sections (3-μm thick) were stained with hematoxylin and eosin (HE) and MT. For evaluation of the degree of peritoneal thickening, the thickness of the submesothelial compact zone (membrane area extending from the lower limit of the mesothelial layer to the upper limit of the muscle layer) was measured in 5 different fields of view, five measurements per field, total 25 points, at ×400 magnification using a microscope (FSX-100, Olympus, Tokyo, Japan). The mean thickness of the submesothelial compact zone in each mouse was calculated and defined as the peritoneal thickness. Immunohistochemical analyses were performed to examine the white blood cell marker CD45, the macrophage marker F4/80, the neutrophil marker Ly6G, the lymphocyte marker CD3, the endothelial marker CD34, and ASC. Briefly, deparaffinized sections were boiled in Target Retrieval Solution (Dako, Agilent Pathology Solutions, Santa Clara, CA), blocked with normal goat serum and 1% bovine serum albumin...
(BSA) in PBS, and incubated overnight with antibodies against CD45 (BD Biosciences, Franklin Lakes, NJ), F4/80 (Abcam, Cambridge, UK), Ly6G (Biolegend, San Diego, CA), CD3 (eBioscience, San Diego, CA), and ASC. This was followed by incubation with Histone Simple Stain Rat MAX PO (Nichirei Corporation, Tokyo, Japan). The immune complexes were detected using a DAB substrate kit (Vector Laboratories, Burlingame, CA). The sections were counterstained with hematoxylin. For immunofluorescence staining for F4/80 and ASC, the sections were incubated with primary antibodies followed by incubation with Alexa 488- or Alexa 594-conjugated secondary antibodies (Thermo Fisher Scientific, Waltham, MA) and nuclei were co-stained with 4′,6-diamidino-2-phenylindole (DAPI; Wako Chemicals, Osaka, Japan). For immunofluorescence staining for CD34 and ASC, double labeling was performed by blocking with unconjugated Fab fragments as described previously.

The sections were first incubated with anti-CD34 antibody (Abcam) followed by incubation with Biotin-conjugated anti-rabbit antibody (Vector Laboratories) and Dylight Streptavidin 488 (Vector Laboratories). The sections were then blocked with 10% normal rabbit serum followed by incubation with AffiniPure Fab Fragment donkey anti-rabbit IgG (40 μg/mL, Jackson ImmunoResearch, West Grove, PA). This was followed by incubation with primary antibodies against ASC and Alexa 548-conjugated secondary antibodies. No signals were detected when an irrelevant IgG (Vector Laboratories) was used instead of the primary antibody as a negative control. The images of the stained sections were digitized and analyzed using a microscope (FSX-100) or confocal laser-scanning microscope (FV-10i, Olympus).

**Real-time RT-PCR analysis.** Real-time RT-PCR analysis was performed as described previously.

Total RNA was prepared from the parietal and visceral peritoneum using ISOGEN (Nippon Gene Co., Ltd., Toyama, Japan) according to the manufacturer’s instructions. Real-time RT-PCR analysis was performed using the Thermal Cycler Dice Real Time Systems II (Takara Bio Inc., Shiga, Japan) to detect mRNA expression. The primers are shown in Supplementary Table S1. The expression levels of each target gene were normalized by subtracting the corresponding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cycle threshold (Ct) values; this was done by using the ΔΔCt comparative method.

**Analysis of peritoneal effluents.** The peritoneal cavity was washed with 2 mL saline after the mice were euthanized. RBC counts in the peritoneal effluents were measured by an automated hematology analyzer (Celltac α, Nihon Kohden, Tokyo, Japan).

**Western blot analysis.** Western blot analysis was performed as described previously. Briefly, cell lysates were prepared using RIPA buffer (20 mM Tris, 2.5 mM EDTA, 1% Triton X, 10% glycerol, 1% deoxycholic acid, 0.1% SDS, 50 mM NaF, and 10 mM Na4P2O7·10H2O), and subjected to SDS-PAGE. The proteins were electrophoretically transferred to PVDF membranes. The membranes were blocked with 5% skim milk in TBS-T for 2 h at room temperature and then incubated overnight at 4 °C with primary antibodies, followed by incubation for 1 h with secondary antibodies conjugated to horseradish peroxidase (HRP). Immunoreactive bands were visualized using a Western Blot Ultra Sensitive HRP Substrate (Takara Bio Inc.). The expression level of β-actin served as an internal control for protein loading. Primary antibodies against ASC, VE-cadherin (Abcam, Cambrige, MA), and β-actin (Sigma-Aldrich) were used. HRP-goat anti-rabbit IgG (Cell Signaling Technology Inc., Boston, MA) and HRP-goat anti-mouse IgG (Cell Signaling) were used as secondary antibodies.

**Cell culture.** Murine primary bone marrow-derived macrophages (BMDMs) were generated as described previously. Briefly, bone marrow cells were isolated from mice and cultured in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS) and 15% conditioned medium of L929 cells (ATCC, Rockville, MD) for 7 days. Primary MLVECs were isolated from the lungs of mice (8–10 weeks old, male) by modifications of a previously described protocol.

After the lungs were perfused with PBS via the pulmonary artery, the lungs were removed and placed in iced 50 mM HEPES buffer (pH 7.4) containing 5 mM KCl, 2.5 mM CaCl2, 2.5 mM MgCl2, 10% FCS, 1% aminopterin, and 2.5 μg/mL kanamycin. The lungs were minced and digested with collagenase (100 U/mL) and dispase (100 U/mL) at 37 °C for 15 min. The resulting cell suspensions were washed with DMEM containing 10% FCS at 37 °C for 5 min. The cells were then incubated with anti-CD45-conjugated magnetic beads and positive selection with anti-CD31-conjugated magnetic beads. Endothelial cell growth supplement (Sigma-Aldrich), 50 μg/mL endothelial cell growth supplement (Sigma-Aldrich), 50 μg/mL heparin (Sigma-Aldrich), 5 μM SB431542 (R&D Systems, Minneapolis, MN), and 1% antibiotics at 37 °C with 5% CO2 for 72–96 h. Endothelial cells were identified by a cobblestone-like morphology and specific expression for VE-cadherin. MLVECs were cultured with 3–4 passages were used. HUVECs were obtained commercially (ScienCell Research Laboratories, San Diego, CA) and cultured in EC medium (ScienCell Research Laboratories). HUVECs with 5–7 passages were used for the experiments.

**Cell death assay and ROS detection.** Cell death was assessed with SYTOX Green (Thermo Fisher Scientific), a membrane-impermeable DNA dye that enters dead cells. ROS generation was assessed in living cells using DCFDA (Abcam). Nuclei were co-stained with Hoechst33342. Fluorescence intensity was measured by using a multimode microplate reader (Spark TECAN, Switzerland).

**IL-1β assay.** IL-1β levels were measured using a mouse ELISA kit (R&D Systems, Minneapolis, USA) according to the manufacturer’s instructions.

**Statistical analysis.** Data are expressed as the mean ± standard error of the mean (SEM). An unpaired t test was used to compare 2 groups. For comparisons between multiple groups, the significance of differences was determined by one-way analysis of variance (ANOVA) combined with the Tukey–Kramer test. Nonparametric data were analyzed using the Mann–Whitney U test or the Kruskal–Wallis test as appropriate. All analyses were performed using GraphPad Prism Software (ver. 7, San Diego, CA). A p-value of <0.05 was considered statistically significant.
References

1. Jain, A. K., Blake, P., Cordy, P. & Garg, A. X. Global Trends in Rates of Peritoneal Dialysis. *Journal of the American Society of Nephrology* **23**, 533–544 (2012).

2. Devuyst, O., Margetts, P. J. & Topley, N. The pathophysiology of the peritoneal membrane. *J Am Soc Nephrol* **21**, 1077–1085 (2010).

3. Kawaguchi, Y., Kawanishi, H., Muijas, S., Topley, N. & Oreopoulos, D. G. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. *Perit Dial Int* **20**(Suppl 4), S43–S55 (2000).

4. Honda, K. & Oda, H. Pathology of encapsulating peritoneal sclerosis. *Perit Dial Int* **25**(Suppl 4), S19–29 (2005).

5. Zhou, Q., Bajo, M. A., Del Peso, G., Yu, X. & Selgas, R. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. *Kidney Int* **90**, S15–S24 (2016).

6. Nilsson-Thorell, C. B., Muscalu, N., Andren, A. H., Kjellstrand, P. T. & Wieslander, A. P. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. *Perit Dial Int* **13**, 208–213 (1993).

7. Hirahara, I. et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. *Perit Dial Int* **26**, 380–392 (2006).

8. Hirahara, I., Ishibashi, Y., Kaname, S., Kusano, E. & Fujita, T. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. *Nephrol Dial Transplant* **24**, 437–447 (2009).

9. Takahashi, M. NLRP3 inflammasome as a novel player in myocardial infarction. *Int Heart J* **55**, 101–105 (2014).

10. Karasawa, T. & Takahashi, M. Role of NLRP3 Inflammasomes in Atherosclerosis. *J Atheroscler Thromb* **24**, 443–451 (2017).

11. He, Y., Hara, H. & Nunez, G. Mechanism and Regulation of NLRP3 Inflammasome Activation. *Trends Biochem Sci* **41**, 1012–1021 (2016).

12. Kuida, K. et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. *Science* **267**, 2000–2003 (1995).

13. Kawaguchi, M. et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. *Circulation* **123**, 594–604 (2011).

14. Usui, F. et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. *Biochem Biophys Res Commun* **425**, 162–168 (2012).

15. Usui, F. et al. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. *Arterioscler Thromb Vasc Biol* **35**, 127–136 (2015).

16. Komada, T. et al. ASC in renal collecting duct epithelial cells contributes to inflammation and injury after unilateral ureteral obstruction. *Am J Pathol* **184**, 1287–1298 (2014).

17. Komada, T. et al. Role of NLRP3 Inflammasomes for Rhabdomyolysis-induced Acute Kidney Injury. *Sci Rep* **5**, 10901 (2015).

18. Guo, H., Callaway, J. B. & Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeutics. *Nat Med* **21**, 677–687 (2015).

19. Anders, H. J. & Schaefer, L. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. *J Am Soc Nephrol* **25**, 1387–1400 (2014).

20. Wang, W. et al. Inflammasome-independent NLRP3 augments TGF-beta signaling in kidney epithelium. *J Immunol* **190**, 1239–1249 (2013).

21. Hautem, N. et al. The NLRP3 Inflammasome Has a Critical Role in Peritoneal Dialysis-Related Peritonitis. *J Am Soc Nephrol* **28**, 2038–2052 (2017).

22. Kitamura, M. et al. New insights into therapeutic strategies for the treatment of peritoneal fibrosis: learning from histochemical analyses of animal models. *Acta Histochem Cytochem* **47**, 133–143 (2014).

23. Tawada, M. et al. Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients. *PLoS One* **11**, e0154644 (2016).

24. Miyazawa, N. et al. Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. *Free Radic Res* **44**, 101–107 (2010).

25. Moinuddin, Z., Summers, A., Van Dellen, D., Augustine, T. & Herrick, S. E. Encapsulating peritoneal sclerosis—a rare but devastating peritoneal disease. *Front Physiol* **5**, 470 (2014).

26. Bellon, T. et al. Alternative activation of macrophages in human peritoneal disease: implications for peritoneal fibrosis. *Nephrol Dial Transplant* **26**, 2993–3005 (2011).

27. Kushiyama, T. et al. Effects of liposome-encapsulated clodronate on chlorhexidine gluconate-induced peritoneal fibrosis in rats. *Nephrology Dialysis Transplantation* **26**, 3143–3154 (2011).

28. Huen, S. C., Moeckel, G. W. & Cantley, L. G. Macrophage-specific deletion of transforming growth factor-beta1 does not prevent renal fibrosis after severe ischemia-reperfusion or obstructive injury. *Am J Physiol Renal Physiol* **305**, F477–F484 (2013).

29. Neri, M. et al. Transcription factor Nr2f2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression. *Kidney Int* **91**, 387–401 (2017).

30. Nakayama, M. The plasma leak-to-response hypothesis: a working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment. *Perit Dial Int* **25**(Suppl 4), S71–76 (2005).

31. Lopes Barreto, D., Struijk, D. G. & Krediet, R. T. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis. *Am J Kidney Dis* **65**, 748–753 (2015).

32. Barreto, D. L., Coester, A. M., Struijk, D. G. & Krediet, R. T. Can effluent metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients? *Perit Dial Int* **33**, 529–537 (2013).

33. Chen, Z., Martin, M., Li, Z. & Shy, J. Y. Endothelial dysfunction: the role of sterol regulatory element-binding protein–induced NOD-like receptor family pyrin domain-containing protein 3 inflammasome in atherosclerosis. *Curr Opin Lipidol* **25**, 339–349 (2014).

34. Williams, J. D. et al. Morphologic changes in the peritoneal membrane of patients with renal disease. *J Am Soc Nephrol* **13**, 470–479 (2002).

35. Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* **526**, 666–671 (2015).

36. Shi, L. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* **526**, 660–665 (2015).

37. Masumoto, J. et al. ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. *Biochem Biophys Res Commun* **303**, 69–73 (2003).

38. Motani, K. et al. Caspase-1 protein induces apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC)-mediated necrosis independently of its catalytic activity. *J Biol Chem* **286**, 33963–33972 (2011).

39. Vajjhala, P. R. et al. The Inflammasome Adaptor ASC Induces Procaspase-8 Death Effector Domain Filaments. *J Biol Chem* **290**, 29217–29230 (2015).

40. Lee, B. L. et al. ASC- and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages. *Sci Rep* **8**, 3788 (2018).

41. Horai, R. et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. *J Exp Med* **187**, 1463–1475 (1998).

42. Tsutsui, H. et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. *Immunity* **11**, 359–367 (1999).
43. Yamamoto, M. et al. ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules. Genes Cells 9, 1055–1067 (2004).
44. Lamkanfi, M. et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 187, 61–70 (2009).
45. Yajima, N. et al. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation 117, 3079–3087 (2008).
46. Lewis Carl, S. A., Gillette-Ferguson, I. & Ferguson, D. G. An indirect immunofluorescence procedure for staining the same cryosection with two mouse monoclonal primary antibodies. J Histochem Cytochem 41, 1273–1278 (1993).
47. Nakamura, J. et al. Adeno-associated Virus Vector-mediated Interleukin-10 Induction Prevents Vascular Inflammation in a Murine Model of Kawasaki Disease. Sci Rep 8, 7601 (2018).
48. Kobayashi, M. et al. The cardiac glycoside ouabain activates NLRP3 inflammasomes and promotes cardiac inflammation and dysfunction. PLoS One 12, e0176676 (2017).
49. Lee, J. H. et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis. Cell 156, 440–455 (2014).

Acknowledgements
We thank Dr. Hiromichi Yoshizawa (Jichi Medical University) for valuable suggestions. This study was supported by grants from the Japan Society for the Promotion of Science (JSPS) through Grant-in-Aid for Scientific Research (18K08112 to MT), Private University Research Branding Project (MT, DN), Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST: 18gm0610012h0105 to MT), Takeda Science Foundation (MT), and JMU Graduate Student Start-up Award and Student Research Award (EH).

Author Contributions
E.H. and M.T. designed the study concept and experiments. E.T., H.I., T. Komada, T. Karasawa, H.K., S.W., R.K., and E.A. performed the experiments and analyzed the data. T. Kasahara, Y.M., T.A., and D.N. discussed the data and provided scientific advice. E.H. and M.T. wrote the manuscript. M.T. supervised the research.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46504-1.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019